Nalaganje...
Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges
Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease in industrialized economies. With no licensed treatment currently available, together with a growing prevalence that parallels global increases in obesity and type 2 diabetes, NAFLD will dominate the landscape...
Shranjeno v:
| izdano v: | J Clin Exp Hepatol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6728526/ https://ncbi.nlm.nih.gov/pubmed/31516268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jceh.2019.03.002 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|